Ubs Asset Management Americas Inc Bluebird Bio, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$3.02 - $4.05 $342,564 - $459,399	113,432 Added 517.84%	135,337 $411,000
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $624 - $1,635	199 Added 0.92%	21,905 $69,000
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $125,243 - $184,283	21,706 New	21,706 $150,000
Q2 2022 Aug 12, 2022	SELL	$2.94 - $5.23 $192,243 - $341,984	-65,389 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$8.96 - $16.31 $38,590 - $70,247	-4,307 Reduced 6.18%	65,389 $653,000
Q3 2021 Nov 15, 2021	BUY	$11.24 - $21.0 $37,069 - $69,258	3,298 Added 4.97%	69,696 $862,000
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $442,322 - $541,624	-24,519 Reduced 26.97%	66,398 $1.38 Million
Q1 2021 May 14, 2021	SELL	$16.59 - $33.89 $6.56 Million - $13.4 Million	-395,431 Reduced 81.31%	90,917 $1.78 Million
Q4 2020 Mar 01, 2021	BUY	$27.5 - $37.92 $4.16 Million - $5.73 Million	151,127 Added 45.08%	486,348 $13.6 Million
Q3 2020 Nov 13, 2020	BUY	$34.44 - $43.75 $29,790 - $37,843	865 Added 0.26%	335,221 $11.7 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $1.05 Million - $1.79 Million	38,847 Added 13.15%	334,356 $13.2 Million
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $1.63 Million - $3.96 Million	-62,390 Reduced 17.43%	295,509 $8.8 Million
Q4 2019 Feb 14, 2020	SELL	$46.96 - $61.67 $2.45 Million - $3.22 Million	-52,264 Reduced 12.74%	357,899 $20.3 Million
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $3.11 Million - $4.87 Million	52,286 Added 14.61%	410,163 $24.4 Million
Q2 2019 Aug 15, 2019	SELL	$75.84 - $105.21 $6.4 Million - $8.88 Million	-84,364 Reduced 19.08%	357,877 $0
Q1 2019 May 14, 2019	SELL	$64.44 - $104.11 $1.64 Million - $2.65 Million	-25,415 Reduced 5.43%	442,241 $0
Q4 2018 Feb 13, 2019	BUY	$59.1 - $93.26 $3.25 Million - $5.13 Million	55,023 Added 13.33%	467,656 $30 Million
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $30.2 Million - $40 Million	340,052 Added 468.51%	412,633 $0
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $940,103 - $1.2 Million	9,435 Added 14.94%	72,581 $0
Q1 2018 May 14, 2018	SELL	$105.8 - $150.94 $611,312 - $872,131	-5,778 Reduced 8.38%	63,146 $0
Q4 2017 Feb 09, 2018	SELL	$81.25 - $130.7 $12.7 Million - $20.5 Million	-156,533 Reduced 69.43%	68,924 $0
Q3 2017 Nov 13, 2017	BUY	$57.74 - $91.42 $13 Million - $20.6 Million	225,457	225,457 $0

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

Black Rock Inc. New York, NY

15.4M
Shares

$4.63 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.5M
Shares

$3.14 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

4.68M
Shares

$1.4 Million
0.0% of portfolio
Pictet Asset Management Sa Geneva 73, V8

4.67M
Shares

$1.4 Million
0.02% of portfolio
State Street Corp Boston, MA

3.84M
Shares

$1.15 Million
0.0% of portfolio

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $23.1M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account